ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.
ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.
Now among the fastest-scaling monopolar RF devices worldwide, XERF™ has more than tripled its pace of adoption in recent months with Asia-Pacific and North...
Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...
SINGAPORE, June 11, 2026 /PRNewswire/ -- DKSH entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and potential patient access to a...
NEW TAIPEI CITY, June 10, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the Phase III clinical trial...
Scholarship aims to support students of color pursuing careers in dentistry to improve access to representative oral care across the state. SEATTLE, June 10,...
In the news release, The Galien Foundation Announces 2026 Prix Galien UK Award Candidates for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical...
KNOXVILLE, TN, June 10, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (“SafeSpace Global” or the “Company”), a provider of AI-powered physical safety and security solutions for regulated care environments, today announced the launch of its new Addiction Treatment Vertical, supported by a newly executed Master Services Agreement (“MSA”) with Antidote Health Ventures and a conditional funding commitment from Method Five Labs, LLC (“Method Five Labs”).
Bold ideas from four local students are among just 60 semifinalist submissions selected from over 3,700 nationwide to pitch at the Mott Million Dollar...